Home › Funds › Elmind Capital, LP › SNDX
Elmind Capital, LP position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
Elmind Capital, LP reported holding 1,605,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$30.2M, representing 7.47% of its reported portfolio and ranking #3 among its reported holdings. Elmind Capital, LP has disclosed SNDX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's SNDX position evolved
Elmind Capital, LP first disclosed a stake in SNDX in Q4 2025 at 1,855,000 shares (US$39.0M). The position peaked in Q1 2026 at 1,855,000 shares, worth US$43.3M. Across 4 filings, Elmind Capital, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,605,000 shares valued at US$30.2M — a reduction of -250,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.85M | $38.97M | New |
| Q1 2026 | 1.85M | $43.33M | Hold |
| Q2 2026 | 1.85M | $40.55M | Hold |
| Q3 2026 | 1.60M | $30.17M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 28 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$153.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$71.1M), Eversept Partners, LP (US$45.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.15M sh · $153.24M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $71.06M · Q3 2026
- Eversept Partners, LP 2.44M sh · $45.93M · Q3 2026
- Aisling Capital Management LP 1.32M sh · $24.76M · Q3 2026
- Parkman Healthcare Partners LLC 1.11M sh · $20.78M · Q3 2026
- Catalio Capital Management, LP 1.02M sh · $19.24M · Q3 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held SNDX?
Elmind Capital, LP has disclosed SNDX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in SNDX?
As of Q3 2026, Elmind Capital, LP holds 1.60M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $30.17M, representing 7.47% of its reported portfolio and ranking #3.
Has Elmind Capital, LP been buying or selling SNDX?
In the latest 13F filing (Q3 2026), Elmind Capital, LP reduced its position in SNDX. The position peaked in Q1 2026 at 1.85M shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.